Innate Pharma S.A.
IPHA
$1.93
-$0.04-2.03%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 42.01% | 63.06% | 85.98% | 14.42% | -136.19% |
| Total Depreciation and Amortization | -55.90% | -23.44% | 18.86% | 23.58% | 25.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.12% | -97.23% | -95.47% | 0.10% | 15,568.57% |
| Change in Net Operating Assets | 165.23% | 40.41% | -156.00% | -151.58% | -144.87% |
| Cash from Operations | 40.86% | -4.79% | -82.11% | -39.68% | -8.89% |
| Capital Expenditure | 22.02% | 27.43% | 34.14% | 54.39% | 64.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 2,713.79% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 855.58% | 838.61% | 820.65% | 917.07% | 5,611.47% |
| Cash from Investing | 1,057.43% | 1,070.16% | 1,092.21% | 3,619.70% | 268.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -94.85% | -61.01% | -16.54% | -27.94% | -40.11% |
| Issuance of Common Stock | -60.45% | -3.08% | 99.49% | -9.54% | -43.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 156.40% | 156.23% |
| Cash from Financing | -145.04% | -84.77% | -10.09% | -115.00% | -107.07% |
| Foreign Exchange rate Adjustments | -134.36% | 335.82% | 160.80% | 144.63% | 137.00% |
| Miscellaneous Cash Flow Adjustments | -100.00% | -100.00% | -100.00% | 178.95% | 230.43% |
| Net Change in Cash | 95.31% | 68.89% | 25.98% | -128.26% | -2,765.28% |